• 1. Walnut (Juglans regia L.) shell pyroligneous acid: chemical constituents and functional applications
  Ali Jahanban-Esfahlan,Ryszard Amarowicz RSC Adv. 2018 8 22376
• 2. Influence of a urea–formaldehyde resin adhesive on pyrolysis characteristics and volatiles emission of poplar particleboard
  Y. Zhang,Z. B. He,L. Xue,D. M. Chu,J. Mu RSC Adv. 2016 6 12850

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Cyclic ketones
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone

Recent Advances in the Study of 3-Ethyl-2-hydroxycyclopent-2-en-1-one (CAS: 21835-01-8) in Chemical Biology and Pharmaceutical Research

The compound 3-ethyl-2-hydroxycyclopent-2-en-1-one (CAS: 21835-01-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activities, and potential applications in drug development.

Recent studies have highlighted the versatility of 3-ethyl-2-hydroxycyclopent-2-en-1-one as a key intermediate in the synthesis of various bioactive molecules. Its cyclopentenone core structure is particularly noteworthy, as it serves as a scaffold for the development of novel anti-inflammatory and anticancer agents. Researchers have employed advanced synthetic methodologies, including asymmetric catalysis and green chemistry approaches, to optimize the production of this compound with high yield and enantiomeric purity.

In terms of biological activity, 3-ethyl-2-hydroxycyclopent-2-en-1-one has demonstrated promising results in preclinical studies. Its mechanism of action appears to involve the modulation of key cellular pathways, including the NF-κB and Nrf2 signaling cascades, which are critical in inflammation and oxidative stress responses. These findings suggest potential applications in the treatment of chronic inflammatory diseases and certain types of cancer.

Furthermore, recent pharmacological evaluations have explored the compound's pharmacokinetic properties and toxicity profile. Initial results indicate favorable bioavailability and a manageable safety profile, making it a viable candidate for further drug development. However, additional studies are required to fully elucidate its metabolic pathways and potential drug-drug interactions.

The integration of computational chemistry and molecular docking studies has provided deeper insights into the compound's interactions with biological targets. These in silico approaches have identified potential binding sites and have guided the design of derivatives with enhanced efficacy and selectivity. Such advancements underscore the importance of interdisciplinary research in accelerating the development of 3-ethyl-2-hydroxycyclopent-2-en-1-one-based therapeutics.

In conclusion, the ongoing research on 3-ethyl-2-hydroxycyclopent-2-en-1-one (CAS: 21835-01-8) highlights its significant potential in chemical biology and pharmaceutical applications. The compound's unique structural features, coupled with its promising biological activities, position it as a valuable candidate for further investigation. Future studies should focus on optimizing its synthetic routes, expanding its therapeutic applications, and advancing it through clinical trials to fully realize its medicinal potential.

• 199992-75-1(2-Hydroxy-3-methylcyclopent-2-enone hydrate)
• 25684-04-2(2-Cyclopenten-1-one, 2-hydroxy-3-propyl-)
• 53263-58-4(5-Ethyl-2-hydroxy-3-methylcyclopent-2-en-1-one)
• 871482-85-8(2-Cyclopenten-1-one,3-(cyclohexylmethyl)-2-hydroxy-)
• 21834-98-0(3,5-dimethyl-1,2-cyclopentanedione)
• 871482-84-7(2-Cyclopenten-1-one,3-(3,7-dimethyloctyl)-2-hydroxy-)
• 871482-83-6(2-Cyclopenten-1-one,3-decyl-2-hydroxy-)
• 61364-95-2(2-Cyclopenten-1-one, 3,4-diethyl-2-hydroxy-)
• 3400-78-0(2-Cyclohexen-1-one, 2-hydroxy-3-methyl-)
• 80-71-7(2-Hydroxy-3-methylcyclopent-2-enone)